BRPI0922630A2 - "(r)-3-(e)-2-(pirrolidin-33-il)vinil)-5-(tetra-hidropiran-4-ilóxi)piridina, seus sais, suas sínteses e seus usos como ligantes para receptores acetilcolinérgico nicotínicos" - Google Patents

"(r)-3-(e)-2-(pirrolidin-33-il)vinil)-5-(tetra-hidropiran-4-ilóxi)piridina, seus sais, suas sínteses e seus usos como ligantes para receptores acetilcolinérgico nicotínicos"

Info

Publication number
BRPI0922630A2
BRPI0922630A2 BRPI0922630A BRPI0922630A BRPI0922630A2 BR PI0922630 A2 BRPI0922630 A2 BR PI0922630A2 BR PI0922630 A BRPI0922630 A BR PI0922630A BR PI0922630 A BRPI0922630 A BR PI0922630A BR PI0922630 A2 BRPI0922630 A2 BR PI0922630A2
Authority
BR
Brazil
Prior art keywords
tetrahydropyran
yloxy
syntheses
pyrrolidin
pyridine
Prior art date
Application number
BRPI0922630A
Other languages
English (en)
Inventor
Daniel Yohannes
Gary Maurice Dull
Gregory J Gatto
John Genus
Joseph Pike Mitchener Jr
Julio A Munoz
Nikolai Fedorov
Philip S Hammond
Pieter Albert Otten
Scott R Breining
Srinivisa Rao Akireddy
Timothy J Cuthbertson
Original Assignee
Targacept Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Targacept Inc filed Critical Targacept Inc
Publication of BRPI0922630A2 publication Critical patent/BRPI0922630A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
BRPI0922630A 2008-12-01 2009-11-30 "(r)-3-(e)-2-(pirrolidin-33-il)vinil)-5-(tetra-hidropiran-4-ilóxi)piridina, seus sais, suas sínteses e seus usos como ligantes para receptores acetilcolinérgico nicotínicos" BRPI0922630A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11888508P 2008-12-01 2008-12-01
PCT/US2009/066092 WO2010065449A1 (en) 2008-12-01 2009-11-30 (r) -3- (e) -2- (pyrr0lidin-3-yl) vinyl) -5- (tetrahydr0pyran-4-yl0xy) pyridine, its salts, its synthesis and its use as ligand for nicotinic acetylcholinergic receptors

Publications (1)

Publication Number Publication Date
BRPI0922630A2 true BRPI0922630A2 (pt) 2016-01-05

Family

ID=41549744

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0922630A BRPI0922630A2 (pt) 2008-12-01 2009-11-30 "(r)-3-(e)-2-(pirrolidin-33-il)vinil)-5-(tetra-hidropiran-4-ilóxi)piridina, seus sais, suas sínteses e seus usos como ligantes para receptores acetilcolinérgico nicotínicos"
BRPI0922152-2A BRPI0922152A2 (pt) 2008-12-01 2009-11-30 Compostos

Family Applications After (1)

Application Number Title Priority Date Filing Date
BRPI0922152-2A BRPI0922152A2 (pt) 2008-12-01 2009-11-30 Compostos

Country Status (28)

Country Link
US (3) US8153821B2 (pt)
EP (3) EP2358670B1 (pt)
JP (2) JP5698673B2 (pt)
KR (2) KR20110094318A (pt)
CN (2) CN102232072B (pt)
AR (1) AR074239A1 (pt)
AU (2) AU2009322630A1 (pt)
BR (2) BRPI0922630A2 (pt)
CA (2) CA2744197A1 (pt)
CL (2) CL2009002146A1 (pt)
CO (1) CO6382158A2 (pt)
EA (1) EA021054B1 (pt)
EC (1) ECSP11011135A (pt)
ES (1) ES2403022T3 (pt)
HK (1) HK1157778A1 (pt)
IL (2) IL212796A0 (pt)
MX (2) MX2011005712A (pt)
MY (1) MY159040A (pt)
NZ (1) NZ593058A (pt)
PE (1) PE20100467A1 (pt)
RU (1) RU2507197C2 (pt)
SA (1) SA109300715B1 (pt)
SG (2) SG171432A1 (pt)
TW (1) TW201024283A (pt)
UA (1) UA106217C2 (pt)
UY (1) UY32278A (pt)
WO (2) WO2010065447A2 (pt)
ZA (1) ZA201103497B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3279195B1 (en) * 2008-12-01 2020-07-01 Oyster Point Pharma, Inc. Synthesis and novel salt forms of (r)-5-((e)-2-pyrrolidin-3-ylvinyl)pyrimidine
US9145396B2 (en) 2008-12-01 2015-09-29 Targacept, Inc. Synthesis and novel salt forms of (R)-5-((E)-2-pyrrolidin-3ylvinyl)pyrimidine
WO2013116371A1 (en) * 2012-01-30 2013-08-08 Roar Biomedical Inc. Ex vivo plasma enzyme activity assay using inhibitors as a negative control
KR101840526B1 (ko) 2013-02-05 2018-03-20 퍼듀 퍼머 엘피 내변조성 제약 제제
US20160262372A1 (en) * 2015-03-13 2016-09-15 Cornell Kunz Extermination Treatment Appliance And Method
BR112018070497A2 (pt) 2016-04-07 2019-01-29 Oyster Point Pharma Inc métodos e formulações farmacêuticas para tratamento de condições oculares

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK94393A3 (en) * 1992-09-11 1994-08-10 Thomae Gmbh Dr K Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those
IL107184A (en) 1992-10-09 1997-08-14 Abbott Lab Heterocyclic ether compounds that enhance cognitive function
US5852041A (en) 1993-04-07 1998-12-22 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acethylcholine receptors
US5604231A (en) 1995-01-06 1997-02-18 Smith; Carr J. Pharmaceutical compositions for prevention and treatment of ulcerative colitis
US5597919A (en) 1995-01-06 1997-01-28 Dull; Gary M. Pyrimidinyl or Pyridinyl alkenyl amine compounds
JP3745433B2 (ja) * 1995-02-02 2006-02-15 第一製薬株式会社 複素環式化合物
US5585388A (en) 1995-04-07 1996-12-17 Sibia Neurosciences, Inc. Substituted pyridines useful as modulators of acetylcholine receptors
US5583140A (en) 1995-05-17 1996-12-10 Bencherif; Merouane Pharmaceutical compositions for the treatment of central nervous system disorders
IL118279A (en) 1995-06-07 2006-10-05 Abbott Lab Compounds 3 - Pyridyloxy (or Thio) Alkyl Heterocyclic Pharmaceutical Compositions Containing Them and Their Uses for Preparing Drugs to Control Synaptic Chemical Transmission
CZ83499A3 (cs) * 1996-09-13 1999-07-14 Schering Corporation Tricyklické sloučeniny, farmaceutický prostředek je obsahující a jejich použití
TW492957B (en) * 1996-11-07 2002-07-01 Novartis Ag N-substituted 2-cyanopyrrolidnes
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
JPH1171345A (ja) * 1997-08-30 1999-03-16 Nippon Nohyaku Co Ltd 光学活性なピロリジン誘導体及びその中間体並びにそれらの製造法
US6310043B1 (en) 1998-08-07 2001-10-30 Governors Of The University Of Alberta Treatment of bacterial infections
GB9821503D0 (en) 1998-10-02 1998-11-25 Novartis Ag Organic compounds
CA2415468A1 (en) * 2000-07-11 2003-01-10 Yoshio Ogino Ester derivatives
WO2003013526A1 (en) * 2001-08-08 2003-02-20 Merck & Co. Inc. Anticoagulant compounds
US7098331B2 (en) * 2003-03-05 2006-08-29 Targacept, Inc. Arylvinylazacycloalkane compounds and methods of preparation and use thereof
WO2007054777A1 (en) * 2005-11-09 2007-05-18 Orchid Chemicals & Pharmaceuticals Limited Depletion of isomer in cephalosporin antibiotic
EP2038041A4 (en) * 2006-05-12 2010-02-17 Myriad Genetics Inc THERAPEUTIC COMPOUNDS AND THEIR USE AGAINST CANCER

Also Published As

Publication number Publication date
BRPI0922152A2 (pt) 2015-08-18
MX2011005712A (es) 2011-06-17
IL212799A0 (en) 2011-07-31
UY32278A (es) 2011-06-30
ZA201103497B (en) 2012-01-25
US8153821B2 (en) 2012-04-10
AU2009322630A1 (en) 2010-06-10
EP2896619A1 (en) 2015-07-22
ES2403022T3 (es) 2013-05-13
EP2358670B1 (en) 2012-10-24
MX2011005713A (es) 2011-06-17
MY159040A (en) 2016-12-15
US20110269975A1 (en) 2011-11-03
CN102232072B (zh) 2014-09-24
US20120015983A1 (en) 2012-01-19
SA109300715B1 (ar) 2014-06-25
HK1157778A1 (en) 2012-07-06
IL212799A (en) 2013-12-31
CN102227406A (zh) 2011-10-26
CL2009002145A1 (es) 2010-04-30
JP5615836B2 (ja) 2014-10-29
EP2358705A1 (en) 2011-08-24
CL2009002146A1 (es) 2010-04-30
UA106217C2 (en) 2014-08-11
CN102227406B (zh) 2013-07-31
US8633227B2 (en) 2014-01-21
CA2744191A1 (en) 2010-06-10
SG171432A1 (en) 2011-07-28
JP5698673B2 (ja) 2015-04-08
JP2012510473A (ja) 2012-05-10
TW201024283A (en) 2010-07-01
CN102232072A (zh) 2011-11-02
JP2012510472A (ja) 2012-05-10
ECSP11011135A (es) 2011-07-29
AR074239A1 (es) 2010-12-29
WO2010065447A3 (en) 2010-07-22
PE20100467A1 (es) 2010-08-03
KR20110094100A (ko) 2011-08-19
CA2744197A1 (en) 2010-06-10
EP2358670A2 (en) 2011-08-24
AU2009322628A1 (en) 2010-06-10
WO2010065447A2 (en) 2010-06-10
RU2507197C2 (ru) 2014-02-20
SG171876A1 (en) 2011-07-28
EA021054B1 (ru) 2015-03-31
CO6382158A2 (es) 2012-02-15
WO2010065449A1 (en) 2010-06-10
IL212796A0 (en) 2011-07-31
RU2011127004A (ru) 2013-01-10
US20140107163A1 (en) 2014-04-17
KR20110094318A (ko) 2011-08-23
NZ593058A (en) 2013-06-28
EA201170736A1 (ru) 2011-12-30

Similar Documents

Publication Publication Date Title
LTC3170818I2 (lt) Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties formos
BRPI0816075A2 (pt) 2-(fenil substituído)-6-amino-5-alcóxi, tioalcóxi e aminoalquil-4-pirimidinacarboxilatos e seus usos como herbicidas
BRPI0922630A2 (pt) "(r)-3-(e)-2-(pirrolidin-33-il)vinil)-5-(tetra-hidropiran-4-ilóxi)piridina, seus sais, suas sínteses e seus usos como ligantes para receptores acetilcolinérgico nicotínicos"
EP2474533A4 (en) 1- (SUBSTITUTED BENZYL) -5-TRIFLUOROMETHYL-2- (1H) PYRIDONE COMPOUNDS, THEIR SALTS, MANUFACTURING METHOD AND USES
CL2014000534A1 (es) Procesos para preparar {1-{1-[3-fluoro-2-(trifluorometil)isonicotinoil]piperidin-4-il}-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]azetidin-3-il}acetonitrilo y compuestos intermediarios, inhibidores de jak; y compuesto intermediario (3-fluoro-2-(trifluorometil)piridin-4-il)(1,4-dioxa-8-azaspiro[4,5]decan-8-il)metanona.
BRPI1012108A2 (pt) 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octano- ou heptano-nitrila como inibidores de jak
BRPI0908433A2 (pt) pirrolo[2,3-d]piridinas e empregos destas como inibidores tirosina cinase
BRPI0810653A2 (pt) Derivados de ácido nicotínico como moduladores do receptor metabotrópico de glutamato-5.
BRPI1012331A2 (pt) "combinações de substância ativa nematicidas, inseticidas e acaricidas compreendendo piridil-etilbenzamida e inseticidas."
BRPI0910503A2 (pt) compostos, composições farmacêuticas e respectivos usos.
CO7071124A2 (es) Pirazolo[1,5-a]piridina sustituida como inhibidores del receptor de cinasa tropomiosina (trk)
DK2296466T3 (da) Ternære herbicidale sammensætninger, der omfatter aminopyralid og imazamox
IL236922A0 (en) Salts and solid forms of (4))-4)-3-(s-morpholinomethyl)benzyl)oxy)-1-oxoisoindoline-2-yl)piperidine-6,2-dione and compounds containing them and methods of their use
BRPI0918433A2 (pt) combinação herbicida compreendendo difluormetano sulfonilanildas substittuídas por demetoxitriazinila.
BRPI0915897A2 (pt) compostos derivados triazóis, composições farmacêuticas e combinações dos mesmos e seus usos
BRPI0915438A2 (pt) derivados de piridino-piridinonas, o respectivo preparo e a respectiva aplicação em terapêutica.
DK2600719T3 (da) 2-substituerede 8-alkyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-6-carbonnitriler og anvendelser deraf
BRPI0907381A2 (pt) Derivados de carboxamidas azabicíclicos, o respectivo preparo e a respectiva aplicação em terapêutica.
DK2013208T3 (da) Pyridin[3,4-B]pyrazinoner
BRPI0906802A2 (pt) Implemento para cuidado oral.
BRPI0922095A2 (pt) derivados de piridina e pirimidina como inibidores de fosfodiesterase 10
BRPI0921598A2 (pt) derivados de piridina e pirimidina como inibidores de fosfodiesterase 10
BRPI1009372A2 (pt) compostos, composição farmacêutica e respectivos usos
DK2878598T3 (da) Krystallinsk form af 4-[5-(pyridin-4-yl)-1h-1,2,4-triazol-3-yl]pyridin-2-carbonitril
BRPI0822337A2 (pt) Folatos, composições e usos dos mesmos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A ANUIDADE.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2386 DE 27-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.